Understanding SARS-CoV-2-Mediated Inflammatory Responses: From

Currently there is no effective antiviral therapy for SARS-CoV-2 infection, which frequently leads to fatal inflammatory responses and acute lung injury. Here, we discuss the various mechanisms of SARS-CoV-mediated inflammation. We also assume that SARS-CoV-2 likely shares similar inflammatory responses. Potential therapeutic tools to reduce SARS-CoV-2-induced inflammatory responses include various methods to block FcR activation. In the absence of a proven clinical FcR blocker, the use of intravenous immunoglobulin to block FcR activation may be a viable option for the urgent treatment of pulmonary inflammation to prevent severe lung injury. Such treatment may also be combined with systemic anti-inflammatory drugs or corticosteroids. However, these strategies, as proposed here, remain to be clinically tested for effectiveness.

Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions - Jiang - 2022 - MedComm - Wiley Online Library

Single‐cell analyses reveal SARS‐CoV‐2 interference with intrinsic immune response in the human gut

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

SARS-CoV-2 pathogenesis Nature Reviews Microbiology

Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? - The Lancet Respiratory Medicine

SARS-CoV-2 and innate immunity: the good, the bad, and the “goldilocks”

Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools

Frontiers Pathophysiology and clinical management of coronavirus disease ( COVID-19): a mini-review

Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations - The Lancet Respiratory Medicine

Potential role of platelets in COVID‐19: Implications for thrombosis - Research and Practice in Thrombosis and Haemostasis

Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools

An Integrated Radiologic-Pathologic Understanding of COVID-19 Pneumonia

Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities

Platelets Can Associate With SARS-CoV-2 RNA and Are Hyperactivated in COVID-19

JCI Insight - Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases